Growth Metrics

Travere Therapeutics (TVTX) Income from Continuing Operations (2011 - 2026)

Travere Therapeutics posted quarterly Income from Continuing Operations of 36602000.0 for Q1 2026, up 11.22% year-on-year from 32910666.35 in Q1 2025, and down 66.48% on a QoQ basis from 21986000.0 in Q4 2025.

Travere Therapeutics (TVTX) has 16 years of Income from Continuing Operations data on file, last reported at 36602000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Income from Continuing Operations rose 11.22% year-over-year to 36602000.0; the trailing twelve-month figure through Mar 2026 stood at 45637000.0 (up 79.8% YoY), and the FY2025 full-year result was 50261000.0, up 84.32% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 36602000.0, down from 21986000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 25706000.0 in Q3 2025 and bottomed at 135958000.0 in Q1 2024.
  • The 5-year median for Income from Continuing Operations is 80023000.0 (2022), against an average of 65605529.41.
  • The widest annual swing landed in 2022, when Income from Continuing Operations sank 135.87%; it then jumped 146.95% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 85636000.0 in 2022, then slipped by 3.46% to 88596000.0 in 2023, then soared by 31.97% to 60268000.0 in 2024, then soared by 63.52% to 21986000.0 in 2025, then tumbled by 66.48% to 36602000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 36602000.0 (Q1 2026), 21986000.0 (Q4 2025), and 25706000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.99 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -8.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.03 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.40 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 727.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 205.99 Mn
10 Travere Therapeutics 4.14 Bn 4.06 Bn 102.38 Mn -36.60 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -36.60 Mn
Dec 31, 2025 -21.99 Mn
Sep 30, 2025 25.71 Mn
Jun 30, 2025 -12.76 Mn
Mar 31, 2025 -41.23 Mn
Dec 31, 2024 -60.27 Mn
Sep 30, 2024 -54.75 Mn
Jun 30, 2024 -69.65 Mn
Mar 31, 2024 -135.96 Mn
Dec 31, 2023 -88.60 Mn
Sep 30, 2023 -89.24 Mn
Jun 30, 2023 -101.93 Mn
Mar 31, 2023 -96.56 Mn
Dec 31, 2022 -85.64 Mn
Sep 30, 2022 -84.06 Mn
Jun 30, 2022 -80.02 Mn
Mar 31, 2022 -81.75 Mn
Dec 31, 2021 -88.77 Mn
Sep 30, 2021 -35.64 Mn
Jun 30, 2021 -39.01 Mn
Mar 31, 2021 -53.85 Mn
Dec 31, 2020 -121.62 Mn
Sep 30, 2020 -22.55 Mn
Jun 30, 2020 -26.07 Mn
Mar 31, 2020 808,000.00
Dec 31, 2019 -30.26 Mn
Sep 30, 2019 -36.49 Mn
Jun 30, 2019 -38.70 Mn
Mar 31, 2019 -40.98 Mn
Dec 31, 2018 -7.46 Mn
Sep 30, 2018 -54.52 Mn
Jun 30, 2018 -22.33 Mn
Mar 31, 2018 -18.38 Mn
Dec 31, 2017 -17.62 Mn
Sep 30, 2017 -17.79 Mn
Jun 30, 2017 -13.23 Mn
Mar 31, 2017 -11.09 Mn
Dec 31, 2016 -8.60 Mn
Sep 30, 2016 -37.11 Mn
Jun 30, 2016 -13.40 Mn
Mar 31, 2016 11.22 Mn
Dec 31, 2015 -2.47 Mn
Sep 30, 2015 105.58 Mn
Jun 30, 2015 -25.53 Mn
Mar 31, 2015 39.66 Mn
Dec 31, 2014 -29.03 Mn
Sep 30, 2014 -17.98 Mn
Jun 30, 2014 11.81 Mn
Mar 31, 2014 -75.74 Mn
Dec 31, 2013 -12.75 Mn
Sep 30, 2013 -12.01 Mn
Jun 30, 2013 -4.92 Mn
Mar 31, 2013 -4.87 Mn
Aug 31, 2012 -3,500.00
May 31, 2012 -3,509.00
Aug 31, 2011 -3,525.00